

No.: 04/TTr-HĐQT-IMP

Cao Lanh City, April 03rd, 2023

PROPOSAL
On Operating Expenses of the Board of Directors in 2023

To: : The General Meeting of Shareholders 2023.

Pursuant to Articles 25 and Clause 4, Article 33 of Imexpharm Corporation's Charter regulating remuneration and expenses for the Board of Directors;

Pursuant to the Resolution of the Board of Directors No.02/2023/NQ-HĐQT-IMP dated March 10, 2023;

The Board of Directors would like to submit the proposals on total remuneration and operating expenses for the Board of Directors (BOD) in 2023 to the General Meeting of Shareholders for consideration and approval as follows:

1. Remuneration and expenses for the BOD: The allocation ratio is 2% of Profit before tax, and before actual paid expenses for the BOD.
2. Bonus for the BOD and SB when the Company achieves the profit targets:
 - Bonus for the BOD of 1% profit after tax when the Company achieves the profit targets:
 - In the event of over-achievement, the BOD will be rewarded with 5% of the excess profit compared to the planned target.

We would like to seek consideration and approval of the General Meeting of Shareholders.

Recipients:

- As above
- Filing: Admin

ON BEHALF OF BOARD OF DIRECTORS
CHAIRMAN



NGUYEN QUOC DINH